Germany has given a green signal to human clinical trials of a potential coronavirus vaccine, according to a report on Independent.
According to the report, during the first stage, the trial will be conducted on 200 healthy participants between the age of 18 and 55, who will receive several variants of the vaccine, developed by German biotech company BioNTech
In the second stage high-risk candidates will be added to the pool, the report added.
The potential vaccine has been developed by BioNTech and Pfizer and is also awaiting testing approval from the US. Meanwhile, the German organisation is also looking to partner with Fosun Pharma to test its vaccine programme in China.
Addressing reporters, German Health Minister Jens Spahn said it was a “good sign” that vaccines in Germany are at a stage of human trials. He however also cautioned that it will take months before any vaccine is fully tested and be made available for all.
Meanwhile, BioNTech also declined to specify a timeline for when the vaccine might be available.
This is Germany’s first human trial for a coronavirus vaccine as it joins global efforts to crack the deadly virus, which has already killed more than 177,000 people and infected 2.5 million worldwide. The United States and China have begun drug and vaccine tests in humans and a potential vaccine developed by Oxford University researchers is also set to gain UK government approval for human trails.